ARWR ARROWHEAD PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 879407 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY-44,302.3%
TTM EPS YoY-51,000.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-156.9%
Net margin-160.6%
FCF margin-63.0%
EBITDA margin-151.4%
Returns
ROE-280.5%
ROA-46.4%
ROIC (approx.)-492.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets97.1%
Debt / equity0.00x
Current ratio4.14x
Interest coverage-7.55x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-29.0%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-09-30 | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $450.82M | $829.45M | $3.55M | $240.74M | $243.23M |
| R&D expense | $739.14M | $607.16M | $505.87M | $353.19M | $297.31M |
| SG&A expense | $202.04M | $123.94M | $98.76M | $92.55M | $124.43M |
| Operating income | -$707.17M | $98.35M | -$601.08M | -$205.00M | -$178.51M |
| Interest expense | $93.71M | $89.36M | $32.35M | $18.33M | $0 |
| Pretax income | -$723.91M | $51.53M | -$612.46M | -$206.49M | -$172.71M |
| Income tax | -$6.78M | $21.42M | -$2.77M | $2.78M | $3.79M |
| Net income | -$724.21M | -$1.63M | -$599.49M | -$205.28M | -$176.06M |
| EBITDA | -$682.47M | $120.55M | -$584.18M | -$194.30M | -$169.81M |
| EPS (basic) | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 |
| EPS (diluted) | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 |
| Weighted avg. shares (diluted) | 141.63M | 133.76M | 119.78M | 106.75M | 105.43M |
| Balance sheet | |||||
| Cash & equivalents | $62.73M | $226.55M | $102.69M | $110.89M | $108.00M |
| Short-term investments | $1.13B | $692.82M | $578.28M | $292.74M | $0 |
| Receivables | $9.93M | $6.82M | $0 | $0 | $1.41M |
| Inventory | $9.07M | $0 | — | — | — |
| Current assets | $1.29B | $950.64M | $695.47M | $416.47M | $405.30M |
| PP&E, net | $371.31M | $382.51M | $386.03M | $290.26M | $110.30M |
| Intangibles | $5.16M | $6.86M | $8.56M | $10.26M | $11.96M |
| Total assets | $1.74B | $1.39B | $1.14B | $765.55M | $691.94M |
| Current liabilities | $311.34M | $195.49M | $103.17M | $105.46M | $138.85M |
| Total liabilities | $1.69B | $881.88M | $948.74M | $478.39M | $273.60M |
| Shareholders' equity | $50.31M | $466.05M | $185.44M | $271.34M | $398.52M |
| Shares outstanding | 141.29M | 135.70M | 124.38M | 107.31M | 105.96M |
| Cash flow statement | |||||
| Operating cash flow | -$271.95M | $179.55M | -$462.85M | -$153.89M | -$136.13M |
| Capital expenditure | $11.99M | $22.67M | $141.47M | $176.74M | $52.78M |
| Free cash flow | -$283.94M | $156.89M | -$604.32M | -$330.63M | -$188.91M |
| Investing cash flow | -$670.48M | -$129.29M | -$420.07M | -$96.16M | -$5.42M |
| Financing cash flow | $776.82M | $74.01M | $870.52M | $253.05M | $65.19M |
| Depreciation & amortization | $24.70M | $22.20M | $16.90M | $10.70M | $8.70M |
| Stock-based compensation | $68.15M | $63.37M | $73.97M | $78.13M | $120.89M |
Free plan shows the latest 5 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.